Reference : Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Scientific journals : Article
Business & economic sciences : Special economic topics (health, labor, transportation…)
Human health sciences : Rheumatology
http://hdl.handle.net/2268/69620
Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
English
Hiligsmann, Mickaël mailto [Université de Liège - ULg > HEC-Ecole de gestion de l'ULg : UER > Economie industrielle >]
Vanoverberghe, Marie mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Neuprez, Audrey mailto [Université de Liège - ULg > > > 1re an. master compl. méd. phys. & réadapt.]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
2010
Expert Review of Pharmacoeconomics & Outcomes Research
Expert Review
10
4
359-366
Yes
International
1473-7167
[en] Cost-effectiveness ; osteoporosis ; strontium ranelate ; Treatment
[en] Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in United Kingdom, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years of age, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost-effective compared with branded risedronate in osteoporotic women over 75 years. Further analyses are required to assess effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men.
Researchers ; Professionals
http://hdl.handle.net/2268/69620

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
ExpertReviewPha_Hiligsmann.pdfPublisher postprint225.04 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.